Frankfurt am Main (ots) - Pentahotels, die Lifestyle Hotelgruppe, besetzt ihre Geschäftsführung neu und ...
Intervet's Bird Flu Vaccine Receives EU License
Boxmeer, The Netherlands (ots/PRNewswire) - Intervet, a leading animal health company, received approval for its bird flu (avian influenza) vaccine Nobilis(R) Influenza H7N1. As a result, Europe now has a licensed vaccine to protect birds against the H7 field strain. Last year the European Commission approved Nobilis(R) Influenza H5N2. With the registration Intervet confirms its leading position in AI vaccines (including H5N2, H5N6, H7N1, H7N7 and H9N2) to protect chickens and ducks against different strains of bird flu.
The CVMP (Committee for Medicinal Products for Veterinary use) highlighted the fact that the current concerns about avian influenza have mainly focused on H5 strains, but that the danger posed by H7 strains should not be ignored. The world has been suffering from H7 outbreaks for seven years. The Netherlands (2003) and Italy (1999-2000) already reported infections of H7 avian influenza. Similar to H5N1, birds with the H7 avian influenza virus can infect humans, as has been demonstrated in the Netherlands in 2003. The outbreaks resulted in 30 millions birds being culled in the Netherlands, and 13 millions birds in Italy.
Paul van Aarle, Director Institutional Sales at Intervet said: "It is necessary to be prepared for potential outbreaks caused by the H7 virus. Therefore Intervet developed this product and applied for European registration. Fortunately the CVMP/EMEA took the same position and reviewed the vaccine under the accelerated registration procedure. This is an excellent example of how industry and regulators can take their joint responsibility towards society."
The vaccine protects against the different varieties of the highly pathogenic H7 field strain. If embedded in national control programs, vaccination contributes substantially to controlling bird flu and reducing the circulation of the virus in the bird population. By reducing the amount of virus in the field, the chance on infection of people is reduced.
The vaccine contains inactivated virus, and has to be injected in order to get a full immune response. Intervet research is investigating the possibilities for a new vaccine type for mass application avoiding injection.
It is important to differentiate between infected and vaccinated animals. Birds vaccinated with H7N1 produce a different set of antibodies than those birds infected with other variants of the H7 field strain. These antibodies can be monitored using specific diagnostic tests.
With a growing list of countries already using Nobilis(R) Influenza successfully in official governmental avian flu control programs, Intervet has accumulated a wealth of experience in the use of vaccines against bird flu. The company has been working with national governments and international organizations to advise on outbreak control and management as well as vaccination strategies aimed at helping bring avian influenza to a halt. Information on these strategies is available on: www.avian-influenza.com.
Note for the Editor
Intervet, a business unit of Akzo Nobel, based in Boxmeer, the Netherlands, with sales of EUR 1,125 million in 2006, is dedicated to research and development, production and marketing of innovative animal health products. Intervet's product range for use in livestock, companion animals, poultry and fish includes vaccines, antiparasitics, anti-infectives, endocrine products, other pharmaceutical specialties. Intervet operates globally with its own marketing organizations. The company currently employs around 5,300 people.
Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the second quarter will be published on July 24, 2007.
Safe Harbor Statement(x)
This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com. The 2006 Annual Report on Form 20-F will be available at the end of the second quarter of 2007.
(x) Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
ots Originaltext: Intervet
Im Internet recherchierbar: http://www.presseportal.ch
Not for publication - for more information: Suzanne Hendriksen, Tel:
+31-(0)485-58-7893; Media Relations Officer, Fax: +31-(0)485-58-5392;
Intervet International bv, firstname.lastname@example.org